1 de 2
-
24/8/2017 12:15
0
djurjura
Messages postés: 835 -
Membre depuis: 21/2/2008
Hereditary Angioedema Market to be Worth US$3.81 Billion by 2025: Initiatives to Generate Awareness by Physicians and Patient Bodies Drive Growth
PR Newswire
Aug. 23, 2017, 07:30 AM
ALBANY, New York, August 23, 2017 /PRNewswire/ --
Some of the prominent names operating in the global hereditary angioedema market are Pharming Group NV, Shire plc, CSL Limited, Ionis Pharmaceuticals, Inc., iBio Inc., and BioCryst Pharmaceuticals, Inc. As per a report by Transparency Market Research, the global hereditary angioedema market will likely rise at a healthy 9.1% CAGR between 2017 and 2025 to become worth US$3.81 bn by 2025 from US$ 1.73 bn in 2016.
Browse Market Research Report @http://www.transparencymarketresearch.com/hereditary-angioedema-market.html
Superior Healthcare Facilities Makes North America Market Leader
Depending upon the class of drugs, the global hereditary angioedema market can be segmented into C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, and Kallikrein Inhibitor, among others including conventional and pipeline. The C1 esterase inhibitor can be further divided into drugs such as Cinryze, Berinert, and Ruconest. Among them, C1 esterase inhibitor, accounted for more than half the share in the market in 2016 and going forward too, the segment is slated to dominate the market on account of its use in treatment of prophylactic and severe HAE attack. The emergence of novel products will aid the segment to hold on to its leading share in the future.
Geography-wise, North America, Europe, and Rest of the World are the key regions in the global hereditary angioedema market. At present, North America accounts for a leading position and in the upcoming years too is expected to retain its dominant share by rising at a healthy 8.3% CAGR between 2017 and 2025. This is because of the superior healthcare infrastructure and strong support from public and private sector in terms of reimbursements. Increasing knowledge about HAE among patients has resulted better methods of diagnosis of HAE and adoption of specialty drugs for treatment of HAE - this is also expected to catalyze growth in the market.
|
2 de 2
-
24/8/2017 12:21
0
djurjura
Messages postés: 835 -
Membre depuis: 21/2/2008
Voici une Traduction partielle de la communication pharmacologie
En voici le texte...
Le marché de l'angioedème héréditaire atteindra 3,81 milliards de dollars américains d'ici 2025: les initiatives visant à susciter la sensibilisation des médecins et des organismes de patients stimulent la croissance
PR Newswire
23 août 2017, 07h30
ALBANY, New York, 23 août 2017 / PRNewswire / -
Certains des noms éminents opérant sur le marché mondial de l'angioedème héréditaire sont Pharming Group NV, Shire plc, CSL Limited, Ionis Pharmaceuticals, Inc., iBio Inc. et BioCryst Pharmaceuticals, Inc. Selon un rapport de Transparency Market Research, le Global Le marché de l'angioedème héréditaire augmentera vraisemblablement d'une CAGR saine de 9,1% entre 2017 et 2025 pour atteindre une valeur de 3,81 milliards de dollars américains d'ici à 2025, contre 1,73 milliard de dollars américains en 2016.
Parcourir le rapport de recherche de marché @http: //www.transparencymarketresearch.com/hereditary-angioedema-market.html
Les installations de soins de santé supérieures rendent le leader du marché en Amérique du Nord
Selon la classe de médicaments, le marché mondial des angio-œdèmes héréditaires peut être segmenté dans l'inhibiteur de l'ester ester C1, l'antagoniste sélectif du récepteur à la bradykinine B2 et l'inhibiteur de la kallikréine, parmi d'autres incluant le pipeline conventionnel et le pipeline. L'inhibiteur de l'esterase C1 peut être davantage divisé en médicaments tels que Cinryze, Berinert et Ruconest. Parmi ceux-ci, l'inhibiteur de l'esterase C1, a représenté plus de la moitié de la part du marché en 2016, et le segment devrait dominer le marché en raison de son utilisation dans le traitement de l'attaque HAE prophylactique et sévère. L'émergence de nouveaux produits aidera le segment à s'accrocher à sa part de leader dans le futur.
La géographie, l'Amérique du Nord, l'Europe et le reste du monde sont les régions clés du marché mondial de l'angioedème héréditaire. À l'heure actuelle, l'Amérique du Nord représente une position de leader et, dans les années à venir, elle devrait conserver sa part dominante en augmentant de 8,3% de CAGR sain entre 2017 et 2025. Cela s'explique par l'infrastructure de santé supérieure et le soutien solide du public et Secteur privé en termes de remboursements. L'augmentation des connaissances sur les HAE chez les patients a entraîné de meilleures méthodes de diagnostic des HAE et l'adoption de médicaments spécialisés pour le traitement des HAE - ce qui devrait également catalyser la croissance du marché.
|
Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Premium
Renseignements sur la Discussion
Afficher tous les Messages
Retourner à la liste
Rafraîchir
PR Newswire
Aug. 23, 2017, 07:30 AM
ALBANY, New York, August 23, 2017 /PRNewswire/ --
Some of the prominent names operating in the global hereditary angioedema market are Pharming Group NV, Shire plc, CSL Limited, Ionis Pharmaceuticals, Inc., iBio Inc., and BioCryst Pharmaceuticals, Inc. As per a report by Transparency Market Research, the global hereditary angioedema market will likely rise at a healthy 9.1% CAGR between 2017 and 2025 to become worth US$3.81 bn by 2025 from US$ 1.73 bn in 2016.
Browse Market Research Report @http://www.transparencymarketresearch.com/hereditary-angioedema-market.html
Superior Healthcare Facilities Makes North America Market Leader
Depending upon the class of drugs, the global hereditary angioedema market can be segmented into C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, and Kallikrein Inhibitor, among others including conventional and pipeline. The C1 esterase inhibitor can be further divided into drugs such as Cinryze, Berinert, and Ruconest. Among them, C1 esterase inhibitor, accounted for more than half the share in the market in 2016 and going forward too, the segment is slated to dominate the market on account of its use in treatment of prophylactic and severe HAE attack. The emergence of novel products will aid the segment to hold on to its leading share in the future.
Geography-wise, North America, Europe, and Rest of the World are the key regions in the global hereditary angioedema market. At present, North America accounts for a leading position and in the upcoming years too is expected to retain its dominant share by rising at a healthy 8.3% CAGR between 2017 and 2025. This is because of the superior healthcare infrastructure and strong support from public and private sector in terms of reimbursements. Increasing knowledge about HAE among patients has resulted better methods of diagnosis of HAE and adoption of specialty drugs for treatment of HAE - this is also expected to catalyze growth in the market.